BIOLASE ENTERS THE SKIN RESURFACING MARKET IN THE U.S. WITH THE LAUNCH OF A NEW WATERLASE FRACTIONAL HANDPIECE

BIOLASE has launched the Waterlase Fractional Handpiece in the U.S., enhancing skin resurfacing treatments with faster healing and recovery times.

Rhea-AI Summary

BIOLASE has launched the Waterlase Fractional Handpiece in the U.S., enhancing skin resurfacing treatments with faster healing and recovery times. The handpiece is FDA 510(k) cleared and operates on the Waterlase iPlus platform, delivering both ablative and non-ablative treatments. Its proprietary water spray allows for procedures without anesthetics, improving patient comfort. BIOLASE targets the $215 million skin resurfacing market, aiming to increase the adoption of its technology in the dental industry. The handpiece has also shown success in international markets, providing effective solutions in cosmetic procedures.

Positive

• Launch of the Waterlase Fractional Handpiece targets the $215 million skin resurfacing market.
• FDA 510(k) cleared, increasing credibility and marketability.
• No local or topical anesthetic needed for many procedures, enhancing patient comfort.
• Built on the proven Waterlase iPlus platform, ensuring reliability and effectiveness.

Negative

• None.

Argus Session date unavailable

+2.09% session move Open Argus

Details

News Market Reaction – BIOL

The recorded move for BIOL in the trading session of this news was +2.09%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The new handpiece uses advanced, proprietary technology to deliver faster healing and quicker recovery for skin-resurfacing patients

LAKE FOREST, Calif., Feb. 23, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today the U.S. launch of the Waterlase Fractional Handpiece for doctors seeking a faster and more efficient way to perform skin resurfacing.

The Waterlase Fractional Handpiece is FDA 510(k) cleared and built on the patented and proven Waterlase iPlus platform, the leading all-tissue laser in the marketplace. The handpiece can deliver both ablative and non-ablative fractional treatments and provides the doctor with control over the depth of penetration with different parameters and treatment techniques. It can create a uniform, one-dimensional pattern of micro-perforations on the tissue surface for maximum efficacy, offering patients comfortable and effective skin resurfacing treatments with faster healing and quicker recovery time. Utilizing BIOLASE's proprietary water spray, no local or topical anesthetic is required for many procedures, and the ergonomic handpiece fits comfortably in either hand, providing doctors with a faster, easy way to deliver skin resurfacing treatments.

"We're very pleased to announce the launch of this state-of-the-art handpiece in the United States, which works with our current Waterlase iPlus platform to deliver faster and more efficient skin resurfacing," said John Beaver, BIOLASE President and Chief Executive Officer. "I believe this launch will further accelerate the adoption of our Waterlase technology in the dental industry and is consistent with our commitment to provide less invasive, patient-friendly technology for both patients and clinicians and expands our access to the approximately $215 million skin resurfacing market worldwide."

This Waterlase Fractional Handpiece is compatible with version 2.1 or newer of the Waterlase iPlus All-Tissue laser and has experienced success to date in international markets. To learn more about the benefits of the Waterlase Fractional Handpiece, visit https://www.biolase.com/fractional-handpiece/.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2021, BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-enters-the-skin-resurfacing-market-in-the-us-with-the-launch-of-a-new-waterlase-fractional-handpiece-301754078.html

SOURCE BIOLASE, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the Waterlase Fractional Handpiece launched by BIOLASE?

The Waterlase Fractional Handpiece is a new device launched by BIOLASE for skin resurfacing, utilizing advanced technology for faster healing.

When was the Waterlase Fractional Handpiece launched in the U.S.?

The Waterlase Fractional Handpiece was launched in the U.S. on February 23, 2023.

What markets does the Waterlase Fractional Handpiece target?

It targets the approximately $215 million skin resurfacing market.

Is the Waterlase Fractional Handpiece FDA approved?

Yes, it is FDA 510(k) cleared, ensuring its safety and efficacy for use.

How does the Waterlase Fractional Handpiece improve patient comfort?

It utilizes a proprietary water spray that often eliminates the need for local or topical anesthetics during procedures.